Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib

The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available small-molecule tyrosine kinase inhibitor, crizotinib, in a real-world clinical setting. Post-marketing surveillance was performed in Japan to obt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2019-04, Vol.14 (4), p.672-682
Hauptverfasser:	Gemma, Akihiko, Kusumoto, Masahiko, Kurihara, Yasuyuki, Masuda, Noriyuki, Banno, Shigeo, Endo, Yutaka, Houzawa, Hiroyuki, Ueno, Naomi, Ohki, Emiko, Yoshimura, Akinobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anaplastic lymphoma kinase-positive NSCLC Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Carcinoma, Non-Small-Cell Lung - chemically induced Carcinoma, Non-Small-Cell Lung - pathology Child Child, Preschool Crizotinib Crizotinib - adverse effects Crizotinib - pharmacology Female Humans Interstitial lung disease Japan Lung Diseases, Interstitial - chemically induced Lung Diseases, Interstitial - pathology Lung Neoplasms - chemically induced Lung Neoplasms - pathology Male Middle Aged Risk Factors Tyrosine kinase inhibitor Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!